At Gore, we’re one of many U.S. manufacturing companies that contribute to this mission through our work on the CH-47 Chinook ...
Hosted on MSN
Amgen lifts 2026 outlook and expands MariTide trials
Amgen raised its 2026 revenue and non-GAAP EPS guidance after a strong first quarter, driven by 24% growth from six key products. The company expanded its MariTide Phase III program to include ...
Q1 2026 Management View "We had a strong first quarter and are well positioned to achieve our objectives for the year," said (Chairman & CEO Robert Bradway), reiterating that 2026 is "a springboard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results